C07D241/36

Dicyano N-heterocyclic compound, light-emitting material, and light-emitting element in which same is used

Provided are: a dicyano N-heterocyclic compound represented by formula (I) (in the formula, R.sup.3 represents an electron-donating group, and n represents the number of repetitions of the content in brackets and is 0 or 1), the compound having exceptional heat resistance and light emission characteristics; a light-emitting material; and a light-emitting element in which the same is used. ##STR00001##

Method for producing fullerene derivative

This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C═O or S═O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; ##STR00001##
(in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).

Method for producing fullerene derivative

This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C═O or S═O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; ##STR00001##
(in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).

HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF
20210113710 · 2021-04-22 ·

The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.

HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF
20210113710 · 2021-04-22 ·

The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.

PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R.sup.1, R.sup.2, L.sup.1, and L.sup.2 are as defined herein.

##STR00001##

PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.j, R.sup.k, and Q are as defined herein.

##STR00001##

PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.j, R.sup.k, and Q are as defined herein.

##STR00001##

Organic electroluminescent materials and organic electroluminescent devices
10886475 · 2021-01-05 · ·

The present disclosure relates to organic electroluminescent materials and organic electroluminescent devices, in particular, discloses a compound of formula (1), wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently selected from hydrogen, a substituted or unsubstituted C.sub.1-20 alkyl, a substituted or unsubstituted C.sub.3-20 cycloalkyl, a substituted or unsubstituted aromatic hydrocarbyl, or a substituted or unsubstituted aromatic heterocyclic group; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having a hole-transporting ability; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having an electron-transporting ability; A and B each independently represent hydrogen, a substituted or unsubstituted, fused aromatic ring, or a substituted or unsubstituted, fused heteroaromatic ring containing a heteroatom(s) selected from O, N and S. ##STR00001##

Organic electroluminescent materials and organic electroluminescent devices
10886475 · 2021-01-05 · ·

The present disclosure relates to organic electroluminescent materials and organic electroluminescent devices, in particular, discloses a compound of formula (1), wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently selected from hydrogen, a substituted or unsubstituted C.sub.1-20 alkyl, a substituted or unsubstituted C.sub.3-20 cycloalkyl, a substituted or unsubstituted aromatic hydrocarbyl, or a substituted or unsubstituted aromatic heterocyclic group; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having a hole-transporting ability; and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 contains a group having an electron-transporting ability; A and B each independently represent hydrogen, a substituted or unsubstituted, fused aromatic ring, or a substituted or unsubstituted, fused heteroaromatic ring containing a heteroatom(s) selected from O, N and S. ##STR00001##